|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibitors of p38, which have been widely explored in clinical trials for RA, resulted in undesirable increases in nuclear factor κB (NF-κB), JNK, and MEK signaling in SFs in inflammatory, but not mitogenic, contexts.
|
29511118 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HOXD10 silencing suppresses human fibroblast-like synoviocyte migration in rheumatoid arthritis via downregulation of the p38/JNK pathway.
|
30186380 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
PFK15 suppressed TNF-α-induced activation of NF-κB and p38, JNK and ERK MAPK signals in RA FLSs.
|
28239846 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review, mainly discusses the effects of Notch, JNK and ERK signaling pathways on the regulation of macrophage polarization, and the effects of pro-inflammatory factors and/or anti-inflammatory cytokines produced by polarized macrophages in RA.
|
28750350 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These observations indicate that the individual activation of ERK2 and JNK1 pathways contributes to TNF-α-induced IL-8 expression in synovial fibroblasts, which appears to be involved in the progress in RA.
|
28806729 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibitors of p38 MAPK or JNK activation provide protection against inflammation and fibrosis in animal models of kidney disease; however, clinical trials of p38 MAPK and JNK inhibitors in other diseases (rheumatoid arthritis and pulmonary fibrosis) have been disappointing.
|
27226108 |
2016 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Secreted frizzled-related protein 5 suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes through down-regulation of c-Jun N-terminal kinase.
|
24764263 |
2014 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further, JNK levels were inversely correlated with C-reactive protein levels in RA patients.
|
22183962 |
2012 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that IL-17 induction of CCL2/MCP-1 was mediated by the PI3K, ERK, and JNK pathways in RA ST fibroblasts and by the PI3K and ERK pathways in macrophages.
|
20228199 |
2010 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Deficient Gadd45beta expression in RA can contribute to activation of JNK, exacerbate clinical arthritis, and augment joint destruction.
|
19877043 |
2009 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
JNK is a key regulator of matrix metalloproteinase production in rheumatoid arthritis.
|
18713996 |
2008 |
|
Rheumatoid Arthritis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
IL-18 induced phosphorylation of JNK, PKCdelta, p38 MAPK, and activating transcription factor 2 (ATF-2) in RA ST fibroblasts in a time-dependent manner, with JNK-2 being upstream of PKCdelta, ATF-2, and NFkappaB.
|
17530707 |
2007 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies demonstrated that the 2 upstream MAPK kinases (MKK-4 and MKK-7) are phosphorylated in RA synovium and form a complex with JNK in fibroblast-like synoviocytes (FLS).
|
16802349 |
2006 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.
|
14734742 |
2004 |